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PCLINICAL RESEARCH Coronary Artery Disease
Impact of Olmesartan on
Progression of Coronary Atherosclerosis
A Serial Volumetric Intravascular Ultrasound Analysis
From the OLIVUS (Impact of OLmesarten on progression of
coronary atherosclerosis: evaluation by IntraVascular UltraSound) Trial
Atsushi Hirohata, MD,* Keizo Yamamoto, MD,* Toru Miyoshi, MD,† Kunihiko Hatanaka, MD,†
Satoshi Hirohata, MD,† Hitoshi Yamawaki, MD,‡ Issei Komatsubara, MD,§ Masaaki Murakami, MD,*
Eiki Hirose, MD,* Shinji Sato, MD,* Keisuke Ohkawa, MD,* Makoto Ishizawa, MD,*
Hirosuke Yamaji, MD,* Hiroshi Kawamura, MD,* Shozo Kusachi, MD, Takashi Murakami, MD,*
Kazuyoshi Hina, MD,* Tohru Ohe, MD*
Okayama, Tottori, and Tsuyama, Japan
Objectives The aim of this study was to evaluate the impact of olmesartan on progression of coronary atherosclerosis.
Background Prior intravascular ultrasound (IVUS) trial results suggest slowing of coronary atheroma progression with some
medicines but have not shown convincing evidence of regression with angiotension-II receptor blocking agents.
Methods A prospective, randomized, multicenter trial—OLIVUS (Impact of OLmesartan on progression of coronary athero-
sclerosis: evaluation by IntraVascular UltraSound)—was performed in 247 stable angina pectoris patients with
native coronary artery disease. When these patients underwent percutaneous coronary intervention for culprit
lesions, IVUS was performed in their nonculprit vessels (without angiographically documented coronary stenosis
[50%]). Patients were randomly assigned to receive 10 to 40 mg of olmesartan or control and treated with a
combination of beta-blockers, calcium channel blockers, diuretics, nitrates, glycemic control agents, and/or
statins per physician’s guidance. Serial IVUS examinations (baseline and 14-month follow-up) were performed to
assess coronary atheroma volume. Volumetric IVUS analyses included lumen, plaque, vessel volume, percent
atheroma volume (PAV), percent change in total atheroma volume (TAV) and PAV.
Results Patient characteristics and blood pressure control were identical between the 2 groups. However, follow-up IVUS
showed significantly decreased TAV and percent change in PAV in the olmesartan group (5.4% vs. 0.6 % for TAV
and 3.1% vs. 0.7% for percent change in PAV, control vs. olmesartan, p  0.05 for all).
Conclusions These observations suggest a positive role in a potentially lower rate of coronary atheroma progression through
the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina
pectoris. (J Am Coll Cardiol 2010;55:976–82) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.062m
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bxtensive cardiovascular disease is the major cause of
orbidity and mortality in patients with angina pectoris.
herefore, optimal atheroma management is a key strategy
or preventing subsequent cardiovascular events. Prior in-
ravascular ultrasound (IVUS) trials have reported a slowing
f coronary atheroma progression or regression with some
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suyama, Japan; and the Okayama University Graduate School of Health Sciences,
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Manuscript received June 16, 2009; revised manuscript received August 10, 2009,
ccepted September 14, 2009.edicines, such as statins or pioglitazone, suggesting the
ossibility for pharmacological interventions (1–13). By
ontrast, chronic activation of the renin-angiotensin
ystem is a well-established contributor to the develop-
ent and progression of atherosclerosis (14). Although
See page 983
ngiotension-II receptor blocking agents (ARBs) are
idely used for the treatment of hypertension, their anti-
nflammatory or antioxidized efficacy through directly
locking the action of angiotensin-II have also been re-
orted (4,15–19). In addition, according to the results of
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March 9, 2010:976–82 ARBs and the Progression of CADecent trials, the similarities of effects on preventing myo-
ardial infarction (MI) between ARB and angiotensin-
onverting enzyme (ACE) inhibitors have also been re-
orted (20). However, the potential advantage beyond
ntihypertensive efficacy for plaque modification has not
een well-clarified in atherosclerotic human coronary arter-
es. Thus, we investigated the impact of administration of
lmesartan, an ARB, on the progression of coronary ath-
rosclerosis as assessed by serial IVUS interrogation.
ethods
atients and study design. The OLIVUS (Impact of
Lmesartan on the progression of coronary atherosclerosis:
valuation by IntraVascular UltraSound) trial is a prospec-
ive, randomized, multicenter trial. The study protocol was
pproved by all participating institutional review boards, and
ll patients provided written informed consent. Patients
ith clinically stable angina pectoris and hypertension
cheduled for percutaneous coronary intervention (PCI)
ere enrolled. After PCI for their culprit lesions, IVUS was
erformed over 40 mm in their nonculprit vessels—defined
s without angiographically documented coronary stenosis
50%—to determine atheroma volume at baseline.
Patients with complicated lesions, such as excessive tor-
uosity or calcified lesions, unable to cross with IVUS,
hronic renal failure (serum creatinine 1.5), unstable
atients, recent MI within 4 weeks, poor ejection fraction
25%, and patients already taking ACE inhibitors or ARBs
ere excluded from the trial. Patients were randomized to
ontrol or olmesartan 10 to 40 mg titrated to maximally
olerated dose by 8 weeks. In addition, patients were treated
ith a combination of beta-blockers, calcium channel
lockers, diuretics, nitrates, glycemic control agents, and/or
tatins per physician’s guidance. After 12 to 16 months,
VUS of the originally examined coronary artery was per-
ormed during the routine follow-up angiogram. Our pri-
ary end point of interest was the impact of administration
f olmesartan on coronary atherosclerotic changes evaluated
y volumetric IVUS. Other outcomes included adverse
vents, such as cardiovascular death, nonfatal MI, nonfatal
troke, noncardiovascular death, hospital stay for unstable
ngina, hospital stay for chronic heart failure, or deteriora-
ion of chronic renal failure.
VUS. The IVUS studies were performed with a commer-
ially available imaging system with a 40-MHz mechanical
ransducer ultrasound catheter (Boston Scientific Corpora-
ion, Natick, Massachusetts). After intracoronary nitroglyc-
rin administration, the imaging catheter was advanced over
he coronary wire to the mid-to-distal vessel under fluoro-
copic guidance. Cine runs, before and during contrast
njection, were performed to define the position of the
atheter distal to an identifiable side branch. With auto-
ated pullback (0.5 mm/s), digital ultrasound images were
btained and recorded on DVDs for subsequent off-line
VUS analysis. The DVDs containing the IVUS pullbacks nere analyzed in a blinded fash-
on by the IVUS core laboratory
n the Sakakibara Heart Institute
f Okayama. After image acqui-
ition, 3-dimensional volumetric
nalysis was performed with
impson’s method by dedicated
oftware (EchoPlaque, Indec
ystems, Mountain View, Cali-
ornia). The operator selected a
istal fiduciary site, usually a
ranch site, as the beginning
oint for analysis. Subsequently,
very 30th frame image was an-
lyzed, generating a series of
ross-sections spaced exactly 0.5
m apart. The final cross-
ection analyzed was obtained at a proximal fiduciary site.
orresponding coronary segments over the 40 mm in the
on–PCI-culprit vessels were selected, and IVUS measure-
ents included vessel, lumen, and total atheroma volume
TAV). To standardize for vessel size, percent atheroma
olume (PAV)—defined as atheroma volume divided by
essel volume—was also calculated. The serial progression
ate of atherosclerosis was compared with change in TAV
nd change in PAV, measured by (follow-up TAV 
aseline TAV)/baseline TAV  100 and (follow-up PAV
baseline PAV)/baseline PAV  100, respectively. A
epresentative case is presented in Figure 1. Intraobserver
ariability has been previously reported (21).
tatistical methods. Analyses were performed with SPSS
ersion 11 software (SPSS, Inc., Chicago, Illinois). Labo-
atory and ultrasound parameters are described with fre-
uencies, whereas continuous variables are reported as
ean, median (with 95% confidence intervals [CIs]), and
Ds. Whether data were normally distributed was examined
y the Kolmogrov-Smirnov test. If data were not normally
istributed, testing for significant differences of each param-
ter between baseline and follow-up was performed with the
ann-Whitney U test. Serial atheroma and PAV changes
ere compared with a 2-tailed, paired Student t test. Linear
egression was applied to determine correlations between
lood pressure reduction and atheroma progression rate.
ultiple linear regression and logistic regression analysis
ere applied to determine the independent predictors of
oronary atheroma changes.
A p value of 0.05 was considered to be statistically
ignificant. In the protocol, the assumptions used for power
alculations required a sample size of 98 patients/treatment
roup to provide 80% power (assuming an SD of 12.5%) to
etect a 5.0% difference in the primary efficacy parameter,
hange in PAV, with a 5% type I error rate for a 2-sided
est. With an anticipated dropout rate of approximately
0%, enrollment of 123 patients/treatment group (total 246
andomized patients) was specified to provide an adequate
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotension-II
receptor blocking agent
IVUS  intravascular
ultrasound
MI  myocardial infarction
PAV  percent atheroma
volume
PCI  percutaneous
coronary intervention
TAV  total atheroma
volumeumber of evaluable IVUS patients.
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ARBs and the Progression of CAD March 9, 2010:976–82esults
etween February 2006 and August 2007, 247 patients with
table angina pectoris undergoing PCI were enrolled in this
rial. During follow-up, 15 patients in the control group and
7 patients in the olmesartan group dropped out from the
rial because of adverse events, laboratory abnormality, or
ithdrawal of consent. Therefore, follow-up IVUS (average
88 54 days) was performed in 215 participants; however,
cases in the control group and 6 cases in the olmesartan
roup were excluded from analysis due to poor IVUS image
uality, such as nonuniform rotational distortion, inconsis-
ent pullback, or large axial movement of the IVUS catheter.
s a result, a total of 205 patients completed the serial
VUS analysis, and average analyzed lengths were 42.6 mm.
he numbers of patients screened and randomized and reasons
or dropping out are reported in Figure 2. Vital status was
scertained in 230 patients (93.1%) at the end of the study. Of
he 109 (86.5%) patients taking olmesartan at the end of the
tudy, 105 (83.3%) were receiving the full dose (20 to 40 mg),
ith only 4 (3.2%) receiving a reduced dose.
atient characteristics and blood pressure changes. Pa-
ient characteristics and medications at baseline are summa-
ized in Tables 1 and 2. All data are identical between the
ontrol and olmesartan groups. At the time of enrollment,
pproximately 30% to 40% of patients were already being
reated with antihypertensive agents, except ACE inhibitor
r ARB and/or statins. Serial changes in blood pressure are
resented in Table 3. In this trial, control of blood pressure
Figure 1 Representative Serial Volumetric IVUS Analysis in the
(A) Baseline intravascular ultrasound (IVUS); (B) 14-month follow-up. Serial changControl Group
es of IVUS parameters are summarized on the right.as at the physician’s discretion except for administration ofFigure 2 Number of Patients Screened and Randomized
and Reasons for Drop-Out in the OLIVUS Trial
CAG  coronary angiography; IVUS  intravascular ultrasound; OLIVUS 
Impact of OLmesartan on progression of coronary atherosclerosis: evaluation
by IntraVascular UltraSound; PCI  percutaneous coronary intervention.
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March 9, 2010:976–82 ARBs and the Progression of CADlmesartan. Although significant improvement of blood
ressure was observed in both groups, there was no signif-
cant difference between the control and olmesartan groups.
ajor cardiovascular events. Adjudicated major cardio-
ascular events are summarized in Table 4. There was no
ifference in terms of cardiovascular death, nonfatal MI or
onfatal stroke, coronary revascularization, hospital stay for
ongestive heart failure, or deterioration for chronic renal
ailure between the 2 groups.
olumetric IVUS analysis. Table 5 summarizes the volu-
etric IVUS results changes in IVUS parameters from
aseline to follow-up. Significant development of atheroma
olume and PAV were found in the control group between
aseline and follow-up (p  0.05). Except for PAV at
aseline, there were no differences in any other IVUS
arameter measured between the control and olmesartan
roups. Table 6 illustrates the results for the nominal and
ercentage change in atheroma volume, which is the pri-
ary efficacy parameter. In a comparison of the 2 regimens,
he progression rate was significantly lower in the olmesar-
aseline MedicationTable 2 Baseline Medication
Control
(n  121)
Olmesartan
(n  126) p Value
Aspirin (%) 100.0 100.0 NS
Beta-blocker (%) 13.2 12.7 NS
Calcium-channel blockers (%) 49.6 41.3 NS
Statins (%) 57.0 52.3 NS
Oral glycemic agents (%) 17.3 19.8 NS
aseline Patientharacteristics and Laboratory ValuesTable 1 Baseline PatientCharacteristics and Laboratory Values
Control
(n  121)
Olmesartan
(n  126) p Value
Male 68 76 NS
Age (yrs) 68.4 8.8 67.8 8.7 NS
Smoking 31 34 NS
Diabetes 35 31 NS
Previous MI 13 15 NS
Analyzed vessel
(LAD/LCX/RCA)
33/33/34 29/31/40 NS
Body mass index (kg/m2) 23.9 3.5 24.7 3.2 NS
Creatinine (mg/dl) 1.0 0.41 0.99 0.25 NS
eGFR (ml/min/1.73 m2) 57.9 19.2 59.6 17.5 NS
HbA1c (%) 5.9 1.2 6.1 1.1 NS
LDL cholesterol (mg/dl) 107.0 30.2 103.8 24.8 NS
HDL cholesterol (mg/dl) 50.4 12.6 47.1 12.7 NS
Triglycerides (mg/dl) 142 64 164 126 NS
Patients already on
antihypertensive agents
38.8 39.7 NS
Patients already on statins 33.0 30.9 NS
alues are %, n, or mean  SD.
eGFR  estimated glomerular filtration rate; HbA1c  hemoglobin A1c; HDL  high-density
ipoprotein; LAD  left anterior descending coronary artery; LCX  left circumflex artery; LDL 
ow-density lipoprotein; MI  myocardial infarction; RCA  right coronary artery.C
ian group (p  0.016 for nominal change in TAV, and p 
.038 for PAV change). The nominal changes in atheroma
olume and PAV were positive in the control group (7.1
m3 and 1.1%, respectively), indicating net progression (p 
.009 and p  0.039 compared with baseline, respectively).
n the olmesartan group, the nominal change in atheroma
olume and PAV were negative (2.6 mm3 and 0.1%,
espectively), showing no disease progression (p  0.34 and
 0.89 compared with baseline, respectively). However, in
his trial, there was no statistically significant correlation
etween blood pressure reduction and atheroma progression
ate. Results of a multiple linear regression test—which is
efined as percentage change of atheroma volume as a
ependent variable—are summarized in Table 7, and results
f logistic regression test for increased atheroma volume
uring follow-up periods are in Figure 3. Both results
dentified olmesartan administration as 1 of the factors that
ecreased atheroma volume. In the diabetic subanalysis,
here was significant difference in PAV changes when
ompared with baseline hemoglobin A1c 6.5% and
6.5% groups (0.40% vs. 5.1%, p  0.01). However, in
he statin subanalysis, there was no difference between the 2
roups. By contrast, there was a difference in PAV change
hen compared with baseline low-density lipoprotein cho-
esterol 120 and 120 mg/dl groups (0.2% vs. 4.1%, p 
.06).
erial Changes in Blood PressureTable 3 Serial Changes in Blood Pressure
Control
(n  121)
Olmesartan
(n  126) p Value
Baseline
Systolic BP (mm Hg) 144.4 23.6* 142.4 24.3 NS
Diastolic BP (mm Hg) 79.2 10.8* 81.1 12.9* NS
14-month follow-up
Systolic BP (mm Hg) 137.9 25.3* 138.4 21.4 NS
Diastolic BP (mm Hg) 74.7 14.6* 77.4 11.3* NS
p  0.05 from baseline.
BP  blood pressure.
utcome for Adjudicatedajor Cardiovascular EventsTable 4 Out ome for AdjudicatedMajor Cardiovascular Events
Control
(n  121)
Olmesartan
(n  126) p Value
Composite of CV death, nonfatal MI,
or nonfatal stroke (%)
2.5 1.6 NS
Cardiovascular death (%) 1.7 0.0 0.31
Nonfatal MI (%) 0.0 1.6 0.17
Nonfatal stroke (%) 0.8 0.0 NS
Noncardiovascular death (%) 0.0 0.0 NS
Hospital stay for unstable angina (%) 0.8 0.0 NS
Coronary revascularization (%) 10.0 7.9 0.61
Hospital stay for CHF (%) 0.8 1.6 NS
Deterioration of CRF (%) 0.8 0.8 NSHF congestive heart failure; CRF chronic renal failure; CV cardiovascular; MImyocardialInsulin (%) 7.1 5.6 NS
nfarction.
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n the present study, significant effect for lower rate of
oronary atheroma progression was observed in patients
eceiving olmesartan, an ARB, compared with the control
roup during the 14-month follow-up period. Currently,
RBs are widely used for the treatment of hypertension.
hey also have beneficial effects on hypertension-related
ardiovascular end organ damage, possibly due to reduction
f oxidative stress and inflammation (14,16–18,22,23).
mong the several ARBs available in the clinical setting,
lmesartan is thought to have a significantly stronger blood
ressure-lowering effect than other ARBs with their respec-
ive starting doses (19). In addition, previous clinical studies
eported the potential decrease of atheromatous plaque
urden in the human artery after administration of olme-
artan or ARB compared with the control group (24,25).
hus, it might be not surprising that olmesartan showed
oronary plaque regression in this trial. However, the
nderlying mechanisms as well as the clinical impact of
RB remain a matter of ongoing debate. According to the
esults of a recent trial, the similarity of effects on reducing
I between ARB and ACE inhibitors should help to dispel
oncerns that ARB might not reduce MI (20). Our study
esults of Serial Volumetric IVUSTable 5 Results of Serial Volumetric IVUS
Control
(n  121)
Olmesartan
(n  126) p Value
IVUS measured lengths (mm) 42.7 42.5 NS
Baseline
Atheroma volume (mm3) 208.8 151.5* 230.2 151.7 NS
Vessel volume (mm3) 494.8 301.2 512.0 307.6 NS
PAV (%) 40.6 10.8† 43.8 10.2 0.03
14-month follow-up
Atheroma volume (mm3) 215.9 156.8* 227.6 145.8 NS
Vessel volume (mm3) 502.5 306.4 509.9 302.7 NS
PAV (%) 41.7 11.5† 43.7 10.4 NS
p  0.01; †p  0.05 between baseline to follow-up.
IVUS  intravascular ultrasound; PAV  percent atheroma volume.
hanges in IVUS Parametersrom Baseline to Follow-UpTable 6 Changes in IVUS ParametersFrom Baseline to Follow-Up
Control
(n  121)
Olmesartan
(n  126) p Value
Nominal change
Atheroma volume (mm3) 7.1 (1.8–12.4)* 2.6 (7.9–2.8) 0.011
Lumen volume (mm3) 0.3 (8.7–9.3) 0.4 (7.6–8.3) 0.989
Vessel volume (mm3) 7.8 (2.5–10.5) 2.1 (8.5–2.5) 0.178
PAV (%) 1.1 (0.1–2.1)† 0.1 (0.9–0.8) 0.085
Change in total atheroma
volume and PAV
Total atheroma volume (%) 5.4 (2.4–8.5) 0.6 (1.9–3.1) 0.016
PAV (%) 3.1 (0.7–5.6) 0.7 (3.4–2.0) 0.038
alue within parentheses indicates 95% confidence interval. *p  0.009; †p  0.039 between
aseline and follow-up.
Abbreviations as in Table 5.ata might show the corroborating efficacy for these medi-
ines in terms of preventing the progression of atheroscle-
osis.
In the present trial, there was no significant effect on the
djudicated major cardiovascular events during the 14-
onth follow-up period. The primary end point of this trial
as change in coronary atheroma volume, assessed by serial
VUS; therefore, we enrolled only a small number of
atients with stable angina. Furthermore, it has been re-
orted that there is a delay of 6 to 12 months before the
enefits of an ARB emerge and that it might take several
ears of treatment for the full benefits to manifest (20).
onger-term follow-up and a larger study might be required
o confirm the long-term results.
There was no significant difference in terms of changes of
lood pressure (26–29). In this trial, control of blood
ressure was left to the physician’s discretion except for
dministration of ARBs and ACE inhibitors; therefore, an
ncremental dose of other antihypertensive agents, such as
eta-blockers, calcium channel blockers, and/or diuretics,
ight have contributed to the similarities in blood pressure
ontrol between the 2 groups.
Previous studies with arbitrary short segment analyses
ave described progression or regression with respect to
theroma volume changes over time in coronary arteries.
Figure 3 Odds Ratio (95% Confidence Interval) for Increased
esults of a Multiple Linear Regression TestTable 7 Results of a Multiple Linear Regression Test
Parameters
Regression
Coefficient SEM p Value
Age 0.09 0.13 0.51
Male 0.61 2.40 0.80
Olmesartan 4.51 2.07 0.03
Statin 1.47 2.07 0.48
Smoking 4.53 2.28 0.048
Baseline HbA1c 1.18 0.93 0.21
ependent variable  atheroma volume change.
HbA1c  hemoglobin A1c.Atheroma Volume During Follow-Up Periods
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March 9, 2010:976–82 ARBs and the Progression of CADowever, plaque deposition is a continuous variable; thus,
rbitrary short segment analyses might not necessarily indi-
ate the degree or extent of atherosclerosis in the entire
oronary tree. In the present study, volumetric IVUS anal-
ses were completed exclusively in entire vessels; therefore,
hese IVUS parameters represent atheroma progression of
easured coronary arteries. According to our serial IVUS
bservations, progression/regression atheroma burden
hrough administration of olmesartan seems to be associated
ith vessel remodeling. These findings are concurrent with
revious studies using statins and might suggest a possi-
le similar atheroma reductive process for ARB (30–32).
n the present study, multivariate analysis identified olme-
artan administration as 1 of the factors that decreased
theroma volume. However, a high proportion of patients in
ur study were already being treated with lipid-lowering
gents, antiplatelet agents, and/or other blood-pressure–
owering drugs, except ARBs or ACE inhibitors, which
ight have minimized the differences in plaque changes
een between the 2 randomized groups, compared with
hose seen in previous trials.
There were several studies assessing temporal changes in
ercent plaque volume with IVUS (1–9,33,34). Compared
ith previous studies, results of the present study seem to
how convincing serial changes of coronary atheroma vol-
me. In the present study, the differences in IVUS param-
ters were relatively small—perhaps associated with this
tudy population having received optimized lipid-lowering
herapy, beta-blockers, and antiplatelet drugs—compared
ith subjects in previous clinical trials. Nevertheless, the
lmesartan group had a substantially lower progression rate
han would have been predicted for the low-density lipopro-
ein cholesterol level achieved. In addition, in the present
rial, there was no statistically significant correlation be-
ween blood pressure reduction and atheroma progression
ate (27,28). This might suggest the potential manifold
ction of olmesartan, apart from the antihypertensive effect,
hat might be beneficial, such as activity leading to atheroma
tabilization and reduction. We believe this is the first
linical trial that shows potential reduced progression of coro-
ary atherosclerosis with an ARB. Our study data might add
nother striking benefit to the ever-growing list of positive
utcomes associated with olmesartan administration.
tudy limitations. First, a small number of patients with
table angina pectoris were enrolled; therefore, some selection
ias might exist. Second, the IVUS results showed relatively
arger SDs; however, these are not unusual for this kind of
tudy. In addition, development of coronary atheroma might
ot be directly associated with the incidence of a cardiovascular
vent; therefore, qualitative plaque assessment, such as virtual
istology-IVUS or optical coherence tomography, and longer-
erm follow-up might also be required. In addition, a high
roportion of patients in our study were already being treated
ith optimal lipid-lowering therapy; therefore, it might be
ifficult to show an effect in addition to that treatment.onclusions
hese observations suggest a positive role in a potentially
ower rate of coronary atheroma progression through the
dministration of olmesartan, an ARB, for patients with
table angina pectoris.
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